Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML).

Trial Profile

Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML).

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2015

At a glance

  • Drugs RG 7356 (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 11 May 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
    • 03 Nov 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 14 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top